Vimarsana
Biggest News Aggregation in the World

Page 21 - Resented News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Resented. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Resented Today - Breaking & Trending Today

Allurion Technologies, Inc.: First Multi-Center Study Combining the Allurion Program With GLP-1 Therapy Presented at the European Congress on Obesity - Vimarsana News

Allurion Technologies, Inc.: First Multi-Center Study Combining the Allurion Program With GLP-1 Therapy Presented at the European Congress on Obesity

Combination therapy led to nearly 19% weight loss at approximately 8 months Allurion, a company dedicated to ending obesity, today announced results from a new study that will be presented at the

Legend Biotech Reports First Quarter 2023 Results and Recent Highlights - Vimarsana News

Legend Biotech Reports First Quarter 2023 Results and Recent Highlights

New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel will be presented at the 2023 American Society of Clinical Oncology ... | May 18, 2023

Copernicus Therapeutics: Newly Presented Preclinical Data Shows Potential for Novel Gene Therapy To Treat Opioid Use Disorder - Second Year of NID/ANIH Grant Support Will Enable Further Exploration of Hypothesis - Vimarsana News

Copernicus Therapeutics: Newly Presented Preclinical Data Shows Potential for Novel Gene Therapy To Treat Opioid Use Disorder - Second Year of NID/ANIH Grant Support Will Enable Further Exploration of Hypothesis

Dr. Barbara Waszczak, Professor of Pharmacology at Northeastern University's Bouvé College of Health Sciences, and collaborators from Cummings School of Veterinary Medicine at Tufts University and Tufts

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases - Vimarsana News

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

Six abstracts to be presented demonstrating efficacy and tolerability of investigational Bylvay in select cholestatic liver diseasesNew data emphasizes the consistent benefit of Bylvay as an... | May 17, 2023

Invitation to Roche's virtual EHA 2023 event: Crovalimab in Hematology and Nephrology - Vimarsana News

Invitation to Roche's virtual EHA 2023 event: Crovalimab in Hematology and Nephrology

We are pleased to invite investors and analysts to participate in our virtual event on Monday, 12June2023, highlighting crovalimab data presented during the... | May 17, 2023